Palvella Therapeutics, Inc. PVLA R2KR3KPHARMA
Company Overview
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -17.1%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -17.13% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +180.24% |
| 6 Months: | +1.22% |
| 3 Months: | -11.76% |
| 1 Month: | -14.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.07 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -17.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PVLA Palvella Therapeutics, Inc. R2KR3KPHARMA | 125.10 | -25.79 | $1.80B | 0.00% | -80.06% | -46.62% | - | -17.13% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.44M | 11.22M | 7.87M | 7.53M | 4.93M | 14.50M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -5.76K | -2.20K | -671.22K | -2.77M | -1.84M | -3.70M | -3.53M | -3.88M | -4.38M | -5.80M | -6.18M | -8.01M | -7.89M | -5.18M | -8.14M | -2.24M | -7.80M | -10.68M | -12.23M | -2.91M | -3.86M | -4.66M | -13.00M | -5.06M | -16.76M | -19.01M | -7.46M | -12.33M | -12.17M | -15.51M | 2.06M | -11.81M | -1.76M | -2.91M | -5.06M | -7.87M | -9.25M | -10.18M | -14.86M | -21.41M |
| Net Income | -5.76K | -2.20K | -779.90K | -2.88M | -2.02M | -3.70M | -3.53M | -3.92M | -4.16M | -5.88M | -6.20M | -7.99M | -10.09M | -7.06M | -8.71M | -203.00K | -6.15M | -10.35M | -11.76M | -2.59M | -3.60M | -4.95M | -14.28M | -4.17M | -15.50M | -16.54M | -5.10M | -10.34M | -9.74M | -13.18M | 3.98M | -10.75M | -2.54M | -4.17M | -6.78M | -8.19M | -9.47M | -11.35M | -15.77M | -21.87M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.09 | -0.26 | -0.07 | -0.25 | -0.24 | -0.07 | -0.14 | - | - | 3.62 | -8.70 | -1.54 | -2.47 | -3.94 | -0.74 | -0.86 | -1.03 | -1.20 | -1.52 |
| R&D Expense | - | - | 1.22M | 1.12M | 926.60K | 1.52M | 1.73M | 2.05M | 3.66M | 4.50M | 4.62M | 5.36M | 5.40M | 6.26M | 7.94M | 9.15M | 11.40M | 14.30M | 13.37M | 13.21M | 12.76M | 11.33M | 11.82M | 16.56M | 15.80M | 18.94M | 14.07M | 11.95M | 13.59M | 13.42M | 14.33M | 9.60M | 984.00K | 1.44M | 3.18M | 4.07M | 5.12M | 6.53M | 9.33M | 12.47M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.43M | 0 | 5.37M | 2.93M | 5.83M | 25.27M | 27.25M | 43.65M | 29.32M | 31.42M | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 18.04M | 11.87M | 14.10M | 38.60M |
| Operating Income | 553.83K | -15.71K | -7.20M | -13.68M | -22.76M | -14.59M | -30.83M | -27.16M | -33.92M | -51.83M | -18.04M | -11.87M | -14.10M | -38.60M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -18.04M | 18.69M | -13.12M | -35.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 0 | 4.32M | 5.82M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -28.58M | 18.69M | -17.43M | -41.72M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | -1.03M | 0 | 0 | 0 |
| Net Income | 66.20K | -15.71K | -9.85M | -14.06M | -22.80M | -17.65M | -26.75M | -25.47M | -37.23M | -45.74M | -27.55M | 18.69M | -17.43M | -41.72M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.68 | -0.71 | -2.46 | 1.60 | -7.83 | -3.71 |
| R&D Expense | 9.41M | - | 5.60M | 8.24M | 19.70M | 22.29M | 41.49M | 55.00M | 46.53M | 66.66M | 52.98M | 8.79M | 8.15M | 22.84M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | May 2013 | Jun 2013 | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.20K | 7.28M | 11.14K | 21.86M | 33.95M | 35.06M | 103.88M | 141.34M | 143.18M | 141.10M | 105.01M | 153.56M | 95.49M | 7.55M | 88.23M | 59.56M |
| Total Equity | 495.70K | - | 4.73K | 585.01K | 10.01K | 18.01M | 31.13M | 25.23M | 11.52M | 39.94M | 38.29M | 51.35M | 31.03M | 50.76M | -93.78M | -74.48M | 62.61M | 27.98M |
| Cash & Equivalents | 6.33M | 0 | 5.20K | 3.69M | 11.14K | 18.47M | 29.35M | 29.36M | 37.88M | 74.87M | - | 62.26M | 70.44M | 117.76M | 38.63M | 7.35M | 83.60M | 57.98M |
| Total Liabilities | - | - | 474 | 6.69M | 1.12K | 3.85M | 2.82M | 9.84M | 92.35M | 101.41M | 104.88M | 89.75M | 73.98M | 102.81M | 67.56M | 11.43M | 25.63M | 31.58M |
| Current Liabilities | - | - | - | 1.77M | - | 3.52M | 2.80M | 8.38M | 45.77M | 48.08M | - | 27.00M | 22.14M | 50.56M | 36.58M | 2.36M | 12.04M | 11.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -15.06K | - | - | - | 49.75M | -1.07M | -52.47M | -45.90M | -7.66M | -14.84M | -13.70M | -10.84M | -25.01M |
| Investing Cash Flow | - | - | - | - | - | -45.88M | -8.88M | 9.84M | 39.21M | -949.00K | - | - | - | - |
| Financing Cash Flow | - | 21.00K | - | - | - | 4.09M | 48.51M | 32.17M | 10.12M | 59.13M | 9.57M | 5.00M | 87.09M | -660.00K |
| Capital Expenditure | -49.47K | -0 | -267.41K | -620.75K | -560.00K | -1.95M | -1.70M | -2.46M | -2.73M | -949.00K | - | - | - | - |
| Free Cash Flow | - | -15.06K | - | - | - | 47.80M | -2.76M | -54.93M | -48.62M | -8.61M | -14.84M | -13.70M | -10.84M | -25.01M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -5.27M | -8.70M | 76.25M | -25.67M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 4.5% | - | -134.2% | -466.6% | -390.3% | -57.7% | -113.1% | -62.2% | -115.7% | -165.0% | - | - | - | - |
| Net Margin % | 0.5% | - | -183.6% | -479.5% | -391.0% | -69.8% | -98.2% | -58.4% | -127.0% | -145.6% | - | - | - | - |
| ROE % | 11.3% | -156.9% | -54.7% | -45.2% | -90.4% | -153.2% | -67.0% | -49.6% | -120.0% | -90.1% | 29.4% | -25.1% | -27.8% | -149.1% |
| ROCE % | 10.1% | - | -39.2% | -43.9% | -85.3% | -25.1% | -33.1% | -23.8% | -40.9% | -50.3% | -30.6% | -228.8% | -18.5% | -80.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Montanova Capital LLC | 7.88% | 1.14M | $157.56M |
| 2 | Jennison Associates LLC | 6.67% | 960.62K | $133.31M |
| 3 | Blackrock Inc. | 6.37% | 918.36K | $127.44M |
| 4 | Frazier Life Sciences Management, L.P. | 6.12% | 882.40K | $122.45M |
| 5 | First Light Asset Management, LLC | 5.36% | 771.90K | $107.12M |
| 6 | BVF Inc. | 4.67% | 672.79K | $93.36M |
| 7 | State Street Corporation | 4.53% | 653.17K | $90.64M |
| 8 | Price (T.Rowe) Associates Inc | 4.43% | 638.87K | $88.66M |
| 9 | Vanguard Capital Management LLC | 3.57% | 513.79K | $71.30M |
| 10 | Frontier Capital Management Company LLC | 3.32% | 478.83K | $66.45M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PVLA
Palvella Therapeutics, Inc. (PVLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE42V2I2X0R4cVdLdGxObF9PVG80aFZib3RFS1doZ1h1VmRIV3E3S19CeGo4MGtXZUdlQXpQLTNYOU10d0ctN3p3RTdxX1NIa1V1UEE?oc=5" target="_blank">Palvella Therapeutics, Inc. (PVLA) Stock Price, News, Qu…
Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Palvella Therapeutics (PVLA) - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMikAJBVV95cUxOVnF3TzBvRkVvNkt4ZFh4Z1QxNTFVLUdndXE2YkhnZDFQMzU0VlZkTDNKYXNkSjBJeUtUNXk0QjBZM2U5YVQ0U0RzU0U4c2xhcTI1N0hKOWlMYzJJTUdvaExTTXc3bzJxejlHYV9mVUx2ZHlHQzhkWlhxTzhQbk83SDRUV1hUS3g5T3lZbT…
PVLA Nov 2026 230.000 call (PVLA261120C00230000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE4zU1NiMXVBQnZlV1F0bHE3WFJ1WW82ZEhCRGstUmFTYTdtVzlJSDFLS1h3anBjaU5YdVcxdm9Ddkc0SmM2QnhDb2JfQm9pNmlJM05OUnM5Y0RJOEVLRmRuNmZTalFqdw?oc=5" target="_blank">PVLA Nov 2026 230.000 call (P…
Palvella Therapeutics director George M. Jenkins disposes of $3.58m PVLA stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQYWZSX19oc0U3SEtZVHZrQy1JcWhXejZZSGJNY21LWmpPRzF3R25tbk9CT2JiQUFJcVhMZ3NjUWVlLXZrSm1acno2Zkh1TmFTUmxGV0JPVTRScXBJR0dVOHpaa3FNLTNQTTQtQTBiRUZBZkotbjZYdExKNGk1b1h0Z2pjQVlqb2h2R0NiZW…
PVLA Nov 2026 230.000 call (PVLA261120C00230000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5iWlB6cnFwcHRyX3I1dXktLXc3R0E0Wnd2V3pwbXRncjNtYzBHTzJqR1RSWk94Q1VDXzk1WTlCbmhWQW1hYU5TOVVTQlVsSlp5ZEg0NDhxNWZ5Q3VtM2x3M2liWEJ6UQ?oc=5" target="_blank">PVLA Nov 2026 230.000 call (P…
PVLA Nov 2026 130.000 put (PVLA261120P00130000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFBlNkw5R2lRaURMZ1JhUDNOZXR0MnF1WDlPVHpxZjM1Tm5HSFM5ZlFfVk90M3FXS1NSbW54Yjl0Q2laOUZIYzBFRWdXaFJFWFNTUkNpNnNKMk94N2ZJUmE3bUNQRF9RZw?oc=5" target="_blank">PVLA Nov 2026 130.000 put (PV…
PVLA — Frequently Asked Questions
What is the current share price of Palvella Therapeutics, Inc. (PVLA)?
As of 2026-10-23 16:27 PDT, Palvella Therapeutics, Inc. (PVLA) trades at $125.10 on NasdaqGM. Its 52-week range is $44.64 to $158.13.
What is the market capitalisation of PVLA?
Palvella Therapeutics, Inc. (PVLA) has a market capitalisation of $1.80B on NasdaqGM.
What is the P/E ratio of PVLA?
PVLA trades at a trailing price-to-earnings (P/E) ratio of -25.79. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 9.99.
What is the return on equity (ROE) of PVLA?
PVLA has a return on equity (ROE) of -46.62%. Its return on capital employed (ROCE) is -80.06%.
Is PVLA a good stock to buy?
This page provides a data-driven analysis of Palvella Therapeutics, Inc. (PVLA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.